Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

399 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized Phase II Trial of Amrubicin Plus Irinotecan Versus Cisplatin Plus Irinotecan in Chemo-naïve Patients With Extensive-Disease Small-Cell Lung Cancer: Results of the Japan Multinational Trial Organization (JMTO) LC 08-01.
Yoshioka H, Ishida T, Atagi S, Tamiya A, Nishimura T, Iwamoto Y, Kanehara M, Kim YH, Korogi Y, Tomii K, Katakami N, Komuta K, Nishikawa M, Gemma A, Yamaki K, Kawahara M, Miyakoshi C, Mio T. Yoshioka H, et al. Among authors: korogi y. Clin Lung Cancer. 2024 Oct 1:S1525-7304(24)00197-9. doi: 10.1016/j.cllc.2024.09.004. Online ahead of print. Clin Lung Cancer. 2024. PMID: 39482146
How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?
Hata A, Katakami N, Yoshioka H, Kunimasa K, Fujita S, Kaji R, Notohara K, Imai Y, Tachikawa R, Tomii K, Korogi Y, Iwasaku M, Nishiyama A, Ishida T. Hata A, et al. Among authors: korogi y. J Thorac Oncol. 2013 Jan;8(1):89-95. doi: 10.1097/JTO.0b013e31827690b5. J Thorac Oncol. 2013. PMID: 23242440 Free article.
Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
Nishiyama A, Katakami N, Yoshioka H, Iwasaku M, Korogi Y, Hata A, Takeshita J, Otsuka K, Nishino K, Uchida J, Okuyama T, Namba Y, Mori M, Fujita S, Morita S. Nishiyama A, et al. Among authors: korogi y. Lung Cancer. 2015 Sep;89(3):301-5. doi: 10.1016/j.lungcan.2015.06.017. Epub 2015 Jun 25. Lung Cancer. 2015. PMID: 26141215
A phase II study of pemetrexed in chemotherapy-naive elderly patients aged ≥ 75 years with advanced non-squamous non-small-cell lung cancer (HANSHIN Oncology Group 003).
Hattori Y, Iwasaku M, Satouchi M, Nishiyama A, Korogi Y, Otsuka K, Fujita S, Katakami N, Mori M, Nishino K, Morita S, Negoro S. Hattori Y, et al. Among authors: korogi y. Jpn J Clin Oncol. 2013 Dec;43(12):1184-9. doi: 10.1093/jjco/hyt159. Epub 2013 Oct 29. Jpn J Clin Oncol. 2013. PMID: 24168805 Clinical Trial.
The clinical characteristics of two anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibody-positive interstitial lung disease patients with polymyositis/dermatomyositis.
Kunimasa K, Arita M, Nakazawa T, Tanaka M, Tsubouchi K, Konishi S, Fukuda Y, Saigusa M, Nakagawa H, Ubukata S, Korogi Y, Fujii T, Mimori T, Ishida T. Kunimasa K, et al. Among authors: korogi y. Intern Med. 2012;51(24):3405-10. doi: 10.2169/internalmedicine.51.7452. Epub 2012 Dec 15. Intern Med. 2012. PMID: 23257529 Free article.
399 results